Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Century Therapeutics ( (IPSC) ).
Century Therapeutics announced that Bristol-Myers Squibb will terminate their collaboration agreement effective March 12, 2025, following BMS’s internal portfolio prioritization. Despite this, Century remains optimistic about the scientific progress made and plans to explore opportunities in acute myeloid leukemia and multiple myeloma, aligning with their strategic review of the pre-clinical pipeline.
More about Century Therapeutics
Century Therapeutics operates in the biotechnology industry, focusing on the development of induced pluripotent stem cell derived therapies, particularly engineered natural killer and gamma delta T cells for treating hematologic malignancies.
YTD Price Performance: -62.35%
Average Trading Volume: 496,839
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $106.3M
See more insights into IPSC stock on TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
